64,845 Shares in DexCom, Inc. $DXCM Acquired by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 64,845 shares of the medical device company’s stock, valued at approximately $4,367,000.

Several other large investors have also recently bought and sold shares of DXCM. Norges Bank bought a new position in DexCom in the 4th quarter worth about $483,356,000. AQR Capital Management LLC boosted its position in shares of DexCom by 597.8% during the 4th quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock valued at $205,932,000 after acquiring an additional 2,658,158 shares during the last quarter. Deutsche Bank AG bought a new stake in shares of DexCom during the 2nd quarter valued at about $164,035,000. Employees Provident Fund Board bought a new stake in shares of DexCom during the 4th quarter valued at about $145,352,000. Finally, J. Stern & Co. LLP grew its holdings in shares of DexCom by 2,114.8% during the fourth quarter. J. Stern & Co. LLP now owns 1,601,973 shares of the medical device company’s stock worth $106,323,000 after purchasing an additional 1,529,641 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Price Performance

DXCM opened at $89.16 on Wednesday. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $33.65 billion, a P/E ratio of 35.24, a PEG ratio of 1.54 and a beta of 1.41. The stock has a 50-day moving average price of $78.15 and a 200-day moving average price of $71.19. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.DexCom’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period last year, the firm posted $0.48 EPS. Equities analysts predict that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other DexCom news, insider Kevin R. Sayer sold 26,756 shares of DexCom stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the transaction, the insider directly owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. This trade represents a 7.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total transaction of $358,576.00. Following the completion of the sale, the executive vice president owned 100,361 shares of the company’s stock, valued at approximately $7,326,353. The trade was a 4.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,035 shares of company stock valued at $5,446,673 over the last ninety days. Insiders own 0.28% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Wells Fargo & Company upped their price objective on shares of DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. BTIG Research reiterated a “buy” rating and set a $90.00 target price (up from $80.00) on shares of DexCom in a research report on Friday, July 31st. Robert W. Baird set a $105.00 price target on shares of DexCom in a research note on Friday, July 31st. Argus increased their price target on shares of DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Finally, William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.71.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.